3/A - PMGC Holdings Inc. (0001840563) (Issuer)

3/A - PMGC Holdings Inc. (0001840563) (Issuer)

3 - PMGC Holdings Inc. (0001840563) (Issuer)

4 - PMGC Holdings Inc. (0001840563) (Issuer)

3/A - PMGC Holdings Inc. (0001840563) (Issuer)

4 - PMGC Holdings Inc. (0001840563) (Issuer)

3/A - Elevai Labs Inc. (0001840563) (Issuer)

3/A - Elevai Labs Inc. (0001840563) (Issuer)

8-K - PMGC Holdings Inc. (0001840563) (Filer)

424B5 - PMGC Holdings Inc. (0001840563) (Filer)

SCHEDULE 13G/A - PMGC Holdings Inc. (0001840563) (Subject)

8-K - PMGC Holdings Inc. (0001840563) (Filer)

8-K - PMGC Holdings Inc. (0001840563) (Filer)

8-K - PMGC Holdings Inc. (0001840563) (Filer)

8-K - PMGC Holdings Inc. (0001840563) (Filer)

424B5 - PMGC Holdings Inc. (0001840563) (Filer)

8-K - PMGC Holdings Inc. (0001840563) (Filer)

8-K - PMGC Holdings Inc. (0001840563) (Filer)

DENVER, Feb. 19, 2026 (GLOBE NEWSWIRE) -- U.S. equity markets are pointing modestly lower this Thursday morning. The focus remains on earnings season kickoff and any fresh Fed commentary, but today's headlines are dominated by transformative deals and production milestones that are lifting small- and mid-cap names. Key Movers & Catalysts Driving the Tape Interactive Strength (NASDAQ:TRNR) is the standout gainer pre-market, surging more than 40% after announcing a definitive agreement to acquire Ergatta, the game-based connected fitness pioneer. The deal boosts TRNR's 2026 pro forma revenue guidance by 50%, to more than $30 million, with Ergatta alone expected to deliver > $10 million in

NEWPORT BEACH, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- NorthStrive Biosciences, Inc. ("NorthStrive" or the "Company"), a wholly owned subsidiary of PMGC Holdings Inc. (NASDAQ:ELAB), today announced the filing of ten (10) new U.S. patent applications expanding its proprietary EL-22 and EL-32 technologies into animal health and agricultural markets, including applications designed to encourage animals to grow new muscle and increase muscle weight return per animal. These ten (10) patent applications include five (5) new patent applications covering EL-22 and five (5) new, corresponding applications covering EL-32 across multiple farmed animal categories, including livestock, aquaculture

VANCOUVER, British Columbia, Feb. 12, 2026 (GLOBE NEWSWIRE) -- GB Capital Ltd. ("GB Capital"), a strategic finance, advisory and management firm, today announced that it served as co-advisor to PMGC Holdings  Inc. (NASDAQ:ELAB) ("PMGC") in connection with PMGC's acquisition of SVM Machining, Inc. ("SVM"), a Northern California–based ISO 9001:2015 certified CNC precision machining company. As disclosed by PMGC in its public announcement of the transaction (available here), the acquisition supports PMGC's strategy of building a scaled, multi-site U.S. precision manufacturing platform through the acquisition and integration of profitable, high-quality operating businesses. Transaction Highl

NEWPORT BEACH, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- NorthStrive Biosciences Inc. ("NorthStrive"), a wholly owned subsidiary of PMGC Holdings Inc. (NASDAQ:ELAB) (the "Company," "PMGC," "we," or "our"), today announced that it has executed a definitive, exclusive license agreement ("License Agreement") with Modulant Biosciences LLC ("Modulant"), following the previously announced binding term sheet dated May 12, 2025. The License Agreement covers NorthStrive's EL-22 and EL-32 assets and, pursuant to its terms, grants Modulant an exclusive, royalty-bearing, sublicensable license to develop, manufacture, and commercialize products derived from these technologies solely for non-human anim

NEWPORT BEACH, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- NorthStrive Biosciences Inc. ("NorthStrive Biosciences"), a subsidiary of PMGC Holdings Inc. (NASDAQ:ELAB) ("PMGC"), today announced a progress update to the anticipated completion timeline for Phase III of its AI Development Program with strategic partner Yuva Biosciences, Inc. ("Yuva Biosciences"). On December 17, 2025, Northstrive Biosciences announced the initiation of Phase III, which was expected to last approximately 6 to 9 weeks. Northstive Biosciences has been advised that Yuva Biosciences has an improved sixth-generation classifier models, representing a significant advancement in screening accuracy and sensitivity which

NEWPORT BEACH, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:ELAB) ("PMGC" or the "Company"), a diversified public holding company announced that it has completed the acquisition of SVM Machining, Inc. ("SVM"). Founded in 1997 by Mark Serpa, SVM (aka Silicon Valley Manufacturing) is a Northern California-based ISO 9001:2015 Certified CNC precision machining and manufacturing services company serving medical, aerospace, biotech & pharmaceutical, semiconductor, and transportation markets. This transaction represents PMGC's third California based CNC machine shop acquisition to date, expanding PMGC's growing footprint in precision manufacturing and furthering its stra

NEWPORT BEACH, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:ELAB) ("PMGC" or the "Company") today announced that, as previously disclosed on January 2, 2026, it will effect a 1-for-4 reverse stock split (the "Split") of its issued and outstanding and authorized common stock, par value $0.0001 per share ("Common Stock"), effective at 9:00 am, Eastern time, on January 6, 2026. Key Details of the Reverse Stock Split: Conversion Ratio: Every 4 shares of issued and outstanding Common Stock will be consolidated into one share of Common Stock, and every 4 shares of authorized Common Stock will be consolidated into one share of Common Stock, each with no further action re

NEWPORT BEACH, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:ELAB) ("PMGC" or the "Company") today announced that it will effect a 1-for-4 reverse stock split (the "Split") of its issued and outstanding and authorized common stock, par value $0.0001 per share ("Common Stock"), effective at 9:00 am, Eastern time, on January 6, 2026. Key Details of the Reverse Stock Split: Conversion Ratio: Every 4 shares of issued and outstanding Common Stock will be consolidated into one share of Common Stock, and every 4 shares of authorized Common Stock will be consolidated into one share of Common Stock, each with no further action required from shareholders.Fractional Shares: S

Certification will Strengthen AGA's Current Position in Aerospace, Defense and Space Manufacturing Sector NEWPORT BEACH, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:ELAB) ("PMGC," the "Company," "we," or "our") today announced that its wholly owned subsidiary, AGA Precision Systems LLC ("AGA"), successfully achieved AS9100 certification, the globally recognized quality management standard specific to the aerospace, defense and space industries. AS9100 is the globally recognized quality management standard for organizations that design, develop, or provide aerospace, defense, space and aviation products and services. With requirements set by the International Aero

Phase III is intended to generate meaningful biological data on potential drug compounds prioritized by YuvaBio's classifier, which applies proprietary machine-learning methods to identify candidates targeting muscle preservation through improvements in mitochondrial function.Experimental work designed to identify candidates that may upregulate ANT1, a key gene involved in metabolic function and muscle integrity.Phase III is expected to accelerate discovery on small-molecule candidates which may promote mitochondrial health and support muscle preservation: using an exclusive dataset on mitochondrial biogenesis, the AI prioritization focuses experimental testing on the most promising candidat

NEWPORT BEACH, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (the "Company" or "PMGC," "our," or "we") (NASDAQ:ELAB), a diversified holding company, is proud to announce its annual sponsorship of TCA Venture Group's ("TCA") Orange County network for 2025. As a Southern California Network Sponsor, PMGC is actively pursuing investments and M&A opportunities to strengthen its portfolio while fostering local business growth and expanding its market presence. TCA Venture Group (formerly known as Tech Coast Angels) is one of the largest and most active angel investor networks in the United States. With a history spanning over 25 years, TCA has been instrumental in funding early-s

Professor of Medicine at the University of California, Los Angeles (UCLA), where he serves as Director of the UCLA Metabolism Research Theme.Over 180 publications in the field of obesity & metabolism, along with multiple NIH-funded projects as Principal Investigator.Dr. Shirihai is a renowned researcher regularly invited as a keynote speaker at annual scientific conferences and has consulted for Johnson & Johnson, Bayer, AstraZeneca and Pfizer, among other healthcare companies. NEWPORT BEACH, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ:ELAB) ("Elevai" or the "Company"), a pioneering force in medical aesthetics, announced the appointment of Orian Shirihai, MD, PhD, t

NEWPORT BEACH, Calif., June 14, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ:ELAB) ("Elevai" or the "Company"), a pioneering force in medical aesthetics, announced the formation of a new Scientific Advisory Board to support the advancement of EL-22, a first-in-class engineered probiotic approach, to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. "We are honored to be forming a Scientific Advisory Board with renowned members that possess deep and complementary knowledge in metabolic diseases, obesity, weight management, muscle preservation and physical function in addition to significant experience in clinical

SC 13G - Elevai Labs Inc. (0001840563) (Subject)

SC 13G - Elevai Labs Inc. (0001840563) (Subject)

SC 13G - Elevai Labs Inc. (0001840563) (Subject)

SC 13G - Elevai Labs Inc. (0001840563) (Subject)

SC 13G - Elevai Labs Inc. (0001840563) (Subject)

SC 13D - Elevai Labs Inc. (0001840563) (Subject)

NEWPORT BEACH, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:ELAB) ("PMGC" or the "Company"), a diversified public holding company announced that it has completed the acquisition of SVM Machining, Inc. ("SVM"). Founded in 1997 by Mark Serpa, SVM (aka Silicon Valley Manufacturing) is a Northern California-based ISO 9001:2015 Certified CNC precision machining and manufacturing services company serving medical, aerospace, biotech & pharmaceutical, semiconductor, and transportation markets. This transaction represents PMGC's third California based CNC machine shop acquisition to date, expanding PMGC's growing footprint in precision manufacturing and furthering its stra

Adds $1.39 Million in Cash-Flow-Positive Revenue from a CNC Machining, Mold Manufacturing, and Specialty Metals Operation Serving the Aerospace, Defense, and Industrial Markets.Adds to PMGC's U.S. Manufacturing Revenue Through a Second Bolt-On Acquisition Under Its Roll-Up Strategy, Bringing Estimated Total Annualized Revenue to Over $2.25 Million. NEWPORT BEACH, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:ELAB) (the "Company," "PMGC" or "we"), a diversified public holding company, today announced that it has completed the acquisition of AGA Precision Systems LLC ("AGA"), a California-based CNC machining business that generated over $1.39 million in revenue in 2

Serves over 300 Commercial Clients including Data Centers, Technology Manufacturers and Information Technology (IT) Service Providers.Adds cash flow positive revenue, enhances PMGC's exposure to U.S. semiconductor and artificial intelligence ("AI") infrastructure growth, and marks the launch of its strategic acquisition program targeting U.S. businesses. NEWPORT BEACH, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:ELAB) (the "Company," "PMGC," "we," or "us"), a diversified public holding company, today announced that it has completed the acquisition of Pacific Sun Packaging Inc. ("Pacific Sun") a specialized custom IT packaging company based in San Clemente, Califor

Agreement adds two drug candidates to product pipeline consisting of (i) "EL-22", a clinical stage engineered probiotic expressing myostatin, and (ii) "EL-32", a preclinical engineered probiotic expressing dual myostatin & activin-A.Exclusive license covers global rights excluding South Korea.Clinical and preclinical data supports advancing EL-22, a novel investigational myostatin asset for the treatment of obesity for an investigational new drug "IND" application in 2025. EL-22 has demonstrated significant increase in body weight and restored muscle damage in preclinical mouse models, suggesting potential as a combination to glucagon-like peptide-1 "GLP-1" products to treat obesity. NEWPOR